Neuroprotection in Huntington??s disease: a 2-year study on minocycline
Authors:
- Raphael M BonelliRBRaphael M Bonelli
- Anna K HödlAHAnna K Hödl
- Peter HofmannPHPeter Hofmann
- Hans-Peter KapfhammerHKHans-Peter Kapfhammer
- 1 November 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 19 (6) , 337-342
Abstract
Huntington's disease (HD), a relentlessly progressive neurodegenerative disorder, is characterized by a clinical triad of psychiatric, cognitive and motor disturbances. The antibiotic minocycline, a caspase inhibitor exhibiting antiapoptotic properties, has been shown to prolong survival in the transgenic mouse model of HD. We administrated minocycline to 14 patients with genetically confirmed HD. The patients were psychiatrically, neurologically and neuropsychologically evaluated at baseline, and after 6 and 24 months of treatment, using the Unified HD Rating Scale and a neuropsychological test battery. After 12 months, three patients were lost to follow-up so that 11 patients were analysed at the endpoint. Minocycline was well tolerated. Unlike the expected natural course of HD, patients exhibited stabilization in general motor and neuropsychological function at endpoint, after improving in the first 6 months. Moreover, we found a significant amelioration of psychiatric symptoms that was not apparent after the first 6 months. In detail, the Mini-Mental State Examination, the Total Motor Score, the Total Functional Capacity Scale and the Independence Scale, as the most prominent scales in HD, were stabilized after 3 years of treatment. Our results confirm previous animal studies and indicate a neuroprotective effect of this agent in HD. A long-term, double-blind, placebo-controlled trial appears highly warranted for definitively establishing the value of minocycline in HD.Keywords
This publication has 29 references indexed in Scilit:
- Minocycline is protective in a mouse model of Huntington's diseaseAnnals of Neurology, 2003
- Minocycline for Huntington’s disease: An open label studyNeurology, 2003
- Behavioural abnormalities contribute to functional decline in Huntington's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Successful Multimodality Treatment of Severe Behavioral Disturbance in a Patient With Advanced Huntington’s DiseaseAmerican Journal of Psychiatry, 2001
- Retest effects and cognitive decline in longitudinal follow-up of patients with early HDNeurology, 2001
- Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in miceNature Medicine, 2000
- A prospective evaluation of cognitive decline in early Huntington's diseaseNeurology, 1995
- Functional decline in Huntington's diseaseMovement Disorders, 1995
- Clinical Assessment of Irritability, Aggression, and Apathy in Huntington and Alzheimer DiseaseJournal of Nervous & Mental Disease, 1990
- “Mini-mental state”Journal of Psychiatric Research, 1975